New therapies and gene target advance the treatment and understanding of hard-to-treat... (cent (43 patients) remaining on therapy ...)

New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias

Date:12/6/2010

cent (43 patients) remaining on therapy and 36 percent (24 patients) discontinuing therapy. Of 32 evaluable patients with CML in chronic phase, 30 patients (94 percent) had a complete hematologic response (meaning blood cell counts are in the normal range), and 20 patients (63 percent) had a major cytogenetic response (meaning that no cells containing the Philadelphia chromosome were detected in the bone marrow). Of those achieving a major cytogenetic response, 12 patients had a complete cytogenetic response and eight patients had a partial cytogenetic response. Eighteen of these patients remained on ponatinib for a mean duration of 326 days without progression (range 142 to 599 days) with 13 of these patients having a confirmed response at a second assessment.

Of 11 evaluable patients with CML in chronic phase with a T315I mutation, 11 patients (100 percent) achieved a complete hematologic response and nine patients (82 percent) had a major cytogenetic response (eight of these patients had a complete cytogenetic response). Of 16 evaluable patients with either CML in accelerated or blast phase or with Ph+ ALL, five patients (31 percent) had a major hematologic response, three patients (19 percent) had a major cytogenetic response, and one patient (6 percent) had a minor cytogenetic response. Of nine evaluable patients with CML in accelerated or blast phase or patients with Ph+ ALL with a T315I mutation, three patients (33 percent) had a major hematologic response, and two patients (20 percent) had a major cytogenetic response.

Responses also were seen in heavily refractory patients with no mutations as well as in patients with other mutations who were resistant to currently approved tyrosine kinase inhibitors. For example, there was one complete cytogenetic response and one partial cytogenetic response in two patients with an F317L mutation who had previously failed therapy with imatinib, dasatinib, and nilotinib. Another patient with an F359C muta
'/>"/>

Contact: Lindsey Love
llove@hematology.org
540-538-9326
American Society of Hematology
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. MSU researcher linking breast cancer patients with alternative therapies
2. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
3. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
4. NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)
5. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
6. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
7. Study evaluates costs and benefits associated with new colon cancer therapies
8. New therapies increase survival rates in post-transplant liver cancer patients
9. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
10. Molecular discovery points to new therapies for brain tumors
11. Ovarian cancer study offers vital clues for new therapies

Post Your Comments:

(Date:6/19/2013)... June 19, 2013 Daimer Industries, ... carpet cleaning machines, including reliable truck mount carpet ... grout cleaning machine systems , and other advanced ... XPH-5900I for auto detailing professionals. The powerful machine, ... of Daimer® models, is ideal for maintaining vehicle ...

(Date:6/19/2013)... June 19, 2013 Indosoft Inc., ... ACD for Asterisk, announced today the availability ... This enhancement offers improved options for extracting, consolidating ... for effective contact center management. , Large Asterisk ... captured as it happens from the call center ...

(Date:6/19/2013)... Bonita ™ Hair Skin and Nail ... to many conditions that range from hair breakage and ... Source® has now developed a single serving, rapid response ... not only stronger than the original Bonita formula, but ... community. , Justin Zehrung, Vice President of Essential ...

(Date:6/19/2013)... 2013 The US Drug Watchdog ... been specifically designed to help a recipient of a DePuy ... contains elevated levels of cobalt, and chromium, because we believe ... the device is doing. In the event the cobalt, or ... options the person will need to consider, including possible revision ...

(Date:6/19/2013)... MinuteHound, a leading time and attendance technology ... up to 8% on payroll costs. MinuteHound’s system eliminates ... systems. Their biometric system is simple: Employees place their ... in and out automatically. Employee time clocks ... punching. , Because the fingerprint data is encrypted ...

Breaking Medicine News(10 mins):Health News:Daimer Ships Carpet Cleaners for Car Detailing Steam Cleaner Tasks 2 Health News:Daimer Ships Carpet Cleaners for Car Detailing Steam Cleaner Tasks 3 Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2 Health News:Essential Source ® Improves On Best Selling Bonita ™ Hair Skin and Nail Product 2 Health News:US Drug Watchdog Now Urges Recipients Of A DePuy Pinnacle All Metal Hip Implant To Call Them About A Vital Blood Test To See If Their Hip Implant Device Has Failed 2 Health News:MinuteHound Announces How Cloud Computing Technology Boosts Savings 2 Health News:MinuteHound Announces How Cloud Computing Technology Boosts Savings 3

[0] Daimer Ships Carpet Cleaners for Car Detailing Steam Cleaner Tasks [0] Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity [0] Essential Source ® Improves On Best Selling Bonita ™ Hair Skin and Nail Product [0] US Drug Watchdog Now Urges Recipients Of A DePuy Pinnacle All Metal Hip Implant To Call Them About A Vital Blood Test To See If Their Hip Implant Device Has Failed [0] MinuteHound Announces How Cloud Computing Technology Boosts Savings

... finds, , , , WEDNESDAY, May 27 (HealthDay News) -- ... identified by U.S. researchers, who said their finding could ... researchers, from the Washington University School of Medicine in ... gene in tumors boosts the risk of cancer recurrence ...

... SAN FRANCISCO, May 27 WeissComm Group ... , a social media consulting company founded by ... Media Officer. WeissComm also announced that it has signed a ... focused on social media education, research and training. Pearson will ...

... $60 Million in Purchases Annually, Allowing It to Cut Administrative Costs, ... May 27 News Facts , , ... Ottawa Hospital , a leading academic health center in Ontario, ... Oracle Purchasing , Oracle iSupplier Portal , ...

... Millennium Research Group,s new European dental implant report now ... 27 Millennium Research Group,s (MRG,s) new European ... despite unfavorable economic conditions, the market was valued at ... over $2.7 billion by 2013 as new technologies drive ...

... May 27 The Bank of New York Mellon, ... been appointed collateral trustee, intercreditor agent, indenture trustee and ... facility which will be used to build Niagara Health ... in St. Catharines, Ontario. The $759 million health ...

... Hurricane ResponseCHICAGO, May 27 Feeding America today ... health care company, Abbott, to pre-position nutritional products ... States and Puerto Rico in preparation for the ... 1. Feeding America is the nation,s largest ...

Cached Medicine News:Health News:Gene Mutation May Up Risks of Endometrial Cancer 2 Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 2 Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 3 Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 4 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 2 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 3 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 4 Health News:Increasingly Competitive European Dental Implant Market to Reach Over $2.7 Billion by 2013 Despite Unfavorable Economic Conditions 2 Health News:Increasingly Competitive European Dental Implant Market to Reach Over $2.7 Billion by 2013 Despite Unfavorable Economic Conditions 3 Health News:The Bank of New York Mellon Appointed Trustee and Agent for Niagara Health System's New Health-Care Complex 2 Health News:Feeding America and Abbott Partner For Hurricane Relief 2 Health News:Feeding America and Abbott Partner For Hurricane Relief 3

Gene Mutation May Up Risks of Endometrial Cancer WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite Increasingly Competitive European Dental Implant Market to Reach Over $2.7 Billion by 2013 Despite Unfavorable Economic Conditions The Bank of New York Mellon Appointed Trustee and Agent for Niagara Health System's New Health-Care Complex Feeding America and Abbott Partner For Hurricane Relief

(Date:6/18/2013)... INDIANAPOLIS , June 18, 2013 The ... LLY ) has declared a dividend for ... on outstanding common stock. The dividend ... at the close of business on August 15, 2013. ... a growing portfolio of pharmaceutical products by applying the ...

(Date:6/18/2013)... , June 18, 2013 Remedy ... for healthcare and life sciences research, today announced ... Administration (GSA) IT Schedule 70 supply contract (GS-35F-367AA, ... to provide innovative IT solutions to government agencies ... with this contract, Remedy has placed its products ...

(Date:6/18/2013)... -- Polymer Technology Systems, Inc. (PTS) announced ... to integrate the CardioChek ® PA system ... systems across the country. The CardioChek PA lipid ... Hanson Medical Systems , offers immediate, on-site ... triglycerides, and glucose. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33611LOGO ...

Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3

[0] Lilly Declares Third-Quarter 2013 Dividend [0] Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies [0] Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients

... Ortho Biotech Products, L.P., today announced that it has ... for the treatment of women with recurrent ovarian cancer ... and Drug Administration,s (FDA) recommendation that an additional Phase ... The NDA was submitted to the FDA in November, ...

... April 29, 2011 UBM Canon,s Medical Design ... Medical Design Excellence Awards (MDEA) Lifetime Achievement Award ... a long career have had a demonstrable impact on ... (Logo: http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ) Selected by ...

Cached Medicine Technology:Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin 2 UBM Canon and Medical Design Excellence Awards (MDEA) Announce Winner of Lifetime Achievement Award 2 UBM Canon and Medical Design Excellence Awards (MDEA) Announce Winner of Lifetime Achievement Award 3

Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin UBM Canon and Medical Design Excellence Awards (MDEA) Announce Winner of Lifetime Achievement Award

Blunt Weitlaner Retractor....

Weitlaner Beckmann retractor, sharp prongs, SS....

Baby Weitlaner retractor, blunt, 4"....

Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....

Medicine Products:

Blunt Weitlaner Retractor Weitlaner Beckmann Retractor Baby Weitlaner Retractor Scoville Sharp Curette